Description of a healthy lifestyle intervention for people with serious mental illness taking second-generation antipsychotics

International Journal of Mental Health Nursing

Volumn 20, Issue 6, 2011, Pages 428-437

  Park, Tanya ^a   Usher, Kim ^a   Foster, Kim ^b  

^a JAMES COOK UNIVERSITY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Antipsychotic medication; Healthy lifestyle; Metabolic syndrome; Motivational interviewing; Serious mental illness; Weight prevention

Indexed keywords

NEUROLEPTIC AGENT;

ARTICLE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; EXERCISE; FEEDING BEHAVIOR; HUMAN; MENTAL DISEASE; METABOLIC SYNDROME X; METHODOLOGY; OBESITY; PATIENT EDUCATION; PSYCHIATRIC NURSING; PSYCHOLOGICAL ASPECT; RISK REDUCTION; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; EXERCISE; FEEDING BEHAVIOR; HUMANS; MENTAL DISORDERS; METABOLIC SYNDROME X; OBESITY; PATIENT EDUCATION AS TOPIC; PSYCHIATRIC NURSING; RISK REDUCTION BEHAVIOR; WEIGHT GAIN;

EID: 80155123362     PISSN: 14458330     EISSN: 14470349     Source Type: Journal    
DOI: 10.1111/j.1447-0349.2011.00747.x     Document Type: Article

References (51)

1. Antai-Otong, D. (2004). Metabolic effects associated with atypical antipsychotic medications. Perspectives in Psychiatric Care, 40 (2), 70-72.
2. Australian Bureau of Statistics (2008). Overweight and Obesity in Adults, 2004-2005, Australia, ABS Cat No.4719.0. Canberra: Australian Bureau of Statistics.
3. Australian Government (2005). Go for 2 Fruit and 5 Veg. Canberra: Department of Health and Aging.
4. Ball, M. P., Coons, V. B. & Buchanan, R. W. (2001). A program for treating olanzapine-related weight gain. Psychiatric Services, 52 (7), 967-969.
5. Beebe, L. H. (2008). Obesity in schizophrenia: Screening, monitoring and health promotion. Perspectives in Psychiatric Care, 44 (1), 25-31.
6. Bradshaw, T., Lovell, K., Bee, P. & Campbell, M. (2010). The development and evaluation of a complex health education intervention for adults with a diagnosis of schizophrenia. Journal of Psychiatric and Mental Health Nursing, 17, 473-486.
7. Brown, W. J., Moorhead, G. E. & Marshall, A. L. (2005). Choose Health: Be Active: A Physical Activity Guide for Older Australians. Canberra: Commonwealth of Australia and the Repatriation Commission.
8. Brunero, S. & Lamont, S. (2009). Systematic screening for metabolic syndrome in consumers with severe mental illness. International Journal of Mental Health Nursing, 8 (2), 144-150.
9. Bundy, B. (2004). Changing behaviour: Using motivational interviewing techniques. Journal of the Royal Society of Medicine, 44 (97), 43-47.
10. Citrome, L., Blonde, L. & Damatarca, C. (2005). Metabolic issues in patients with severe mental illness. Southern Medical Association, 98 (7), 714-720.
11. Council of Australian Governments (2006). National Action Plan on Mental Health 2006-2011. Canberra: Australian Government.
12. Devlin, M. J., Yanovski, S. Z. & Wilson, G. T. (2000). Obesity: What mental health professionals need to know. The American Journal of Psychiatry, 157, 854-866.
13. Faulkner, G., Cohn, T. & Remington, G. (2007). Interventions to reduce weight gain in schizophrenia. Cochrane Database of Systematic Reviews, (1), art. no. CD005148.
14. Goff, D. C., Sullivan, L. M., McEvoy, J. P. etal. (2005). A comparison of ten year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophrenia Research, 80, 45-53.
15. Happell, B., Palmer, C. & Tennent, R. (2010). Mental health nurse incentive program: Contributing positive client outcomes. International Journal of Mental Health Nursing, 19, 331-339.
16. Hennekens, C. H., Hennekens, A. R., Hollar, D. & Casey, D. E. (2005). Schizophrenia and increased risks of cardiovascular disease. American Heart Journal, 150 (6), 1115-1121.
17. Holt, R. I. G., Pevelert, R. C. & Byrne, C. D. (2004). Schizophrenia, the metabolic syndrome and diabetes. Diabetic Medicine, 21, 515-523.
18. Holt, R. I. G., Bushe, C. & Citrome, L. (2005). Diabetes and schizophrenia 2005: Are we any closer to understanding the link? Journal of Psychopharmacology, 19 (6), 56-65.
19. International Diabetes Federation (2006). The IDF consensus worldwide definition of the metabolic syndrome. [Cited 8 Jan 2009.] Available from URL.
20. Jennex, A. & Gardner, D. M. (2008). Monitoring and management of metabolic risk factors in outpatients taking antipsychotic drugs: A controlled study. The Candadian Journal of Psychiatry, 53 (1), 34-42.
21. John, A. P., Koloth, R., Dragovic, M. & Lim, S. C. B. (2009). Prevalence of metabolic syndrome among Australians with severe mental illness. Medical Journal of Australia, 190 (4), 176-179.
22. Johnstone, R., Nicol, K., Donaghy, M. & Lawrie, S. (2009). Barriers to uptake of physical activity in community-based patients with schizophrenia. Journal of Mental Health, 18 (6), 523-532.
23. Knowler, W. C., Hamman, R. F., Edelstein, S. L. etal. (Diabetes Prevention Program Research Group). (2005). Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes, 54 (4), 1150-1156.
24. Lambert, T. J. R. (2009). The medical care of people with psychosis [Editorial]. Medical Journal of Australia, 190 (4), 171-172.
25. Lambert, T. J. R. & Chapman, L. H. (2004). Diabetes, psychotic disorders and antipsychotic therapy: A consensus statement. Medical Journal of Australia, 181, 544-548.
26. Lambert, T. J. R. & Newcomer, J. W. (2009). Are the cardiometabolic complications of schizophrenia still neglected? Barriers to care. Pharmacological approaches to the management of schizophrenia. Medical Journal of Australia, 190 (Suppl 4), S39-S42.
27. Lambert, T. J. R., Velakoulis, D. & Castle, D. J. (2003). Pharmacological approaches to the management of schizophrenia. Medical Journal of Australia, 178 (9) (Suppl. 5 May), S57-S61.
28. Lieberman, J., Stroup, T. S., McEvoy, J. etal. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine, 353 (12), 1209-1223.
29. Littrell, K. H., Hilligoss, N. M., Kirshner, C. D., Petty, R. G. & Johnson, C. G. (2003). The effects of an educational intervention on antipsychotic-induced weight gain. Journal of Nursing Scholarship, 35, 237-241.
30. McEvoy, J. P., Meyer, J. M., Goff, D. C. etal. (2005). Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness(CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Research, 80, 19-32.
31. Miller, W. R. & Rollnick, S. (2002). Motivational Interviewing, 2nd edn. London: The Guildford Press.
32. Muir-Cochrane, E. (2006). Medical co-morbidity risk factors and barriers to care for people with schizophrenia. Journal of Psychiatric and Mental Health Nursing, 13 (4), 447-452.
33. National Health and Medical Research Council (2003). Clinical Practice Guidelines for the Management of Overweight and Obesity in Adults. Canberra: Australian Government Department of Health and Ageing.
34. National Health and Medical Research Council (1998). Dietary Guidelines for Australian Adults. Canberra: Australian Government Department of Health and Ageing.
35. National Preventative Health Taskforce (2008). Technical Report No. 1 Obesity in Australia: A Need for Urgent Action. Canberra: Australian Government Department of Health and Ageing.
36. Newcomer, J. W. (2007). Metabolic considerations in the use of antipsychotic medications: A review of recent evidence. The Journal of Clinical Psychiatry, 68 (Sl), 20.
37. Prochaska, J. O. & DiClemente, C. C. (1983). Stages and processes of self-change of smoking: Toward an integrative model of change. Journal of Consulting and Clinical Psychology, 51 (3), 390-395.
38. Prochaska, J. O. & Velicer, W. F. (1997). The transtheroetical model of health behavior change. American Journal of Health Promotion, 12 (1), 38-48.
39. Queensland Government (2006). 10, 000 Steps. Brisbane: Department of Queensland Health. [Cited 7 Jan 2009.] Available from URL.
40. Queensland Health (2008). The Health of Queenslanders 2008:Prevention of Chronic Disease. Second Report of the Chief Health Officer, Queensland. Brisbane: Queensland Government, Department of Health.
41. Robson, D. & Gray, R. (2007). Serious mental illness and physical health problems: A discussion paper. International Journal of Nursing Studies, 44, 457-466.
42. Rollnick, S., Miller, W. R. & Butler, C. C. (2008). Motivational Interviewing in Health Care. New York: The Guildford Press.
43. SANE Australia (2007). Physical health care and mental illness. Research Bulletin. [Cited 7 Feb 2008.] Available from URL.
44. Thakore, J. H., Mann, J. N., Vlahos, I., Martin, A. & Reznek, R. (2002). Increased visceral fat distribution in drug-naïve and drug-free patients with schizophrenia. International Journal of Obesity, 26, 137-141.
45. Tirupati, S. & Chua, L. E. (2007). Obestiy and metabolic syndrome in a psychiatric rehabilitation service. Australian and New Zealand Journal of Psychiarty, 42 (2), 606-610.
46. Tschoner, A., Engl, J., Laimer, M. etal. (2007). Metabolic side effects of antipsychotic medication. International Journal of Clinical Practice, 61 (8), 1356-1370.
47. Usher, K., Foster, K. & Park, T. (2006). The metabolic syndrome and schizophrenia: The latest evidence and nursing guidelines for management. Journal of Psychiatric and Mental Health Nursing, 13 (6), 730-734.
48. Vreeland, B., Minsky, S., Menza, M., Radler, D. R., Roemheld-Hamm, B. & Stern, R. (2003). A program for manging weight gain associated with atypical antipsychotics. Pyschiatric Services, 54 (8), 1155-1157.
49. Wand, T. & Murray, L. (2008). Let's get physical. International Journal of Mental Health Nursing, 17, 363-369.
50. Weber, M. & Wyne, K. (2006). A cognitve/behavioural group intervention for weight loss in patients treated with atypical antipsychotics. Schizophrenia Research, 83, 95-101.
51. World Health Organization (1986). The Ottawa Charter for Health Promotion. Geneva: WHO.